erlotinib has been researched along with alfuzosin in 2 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (alfuzosin) | Trials (alfuzosin) | Recent Studies (post-2010) (alfuzosin) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 427 | 127 | 120 |
| Protein | Taxonomy | erlotinib (IC50) | alfuzosin (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Homo sapiens (human) | 0.018 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.023 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.023 | |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.023 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, EC; Chien, HC; Giacomini, KM; Huang, Y; Khuri, N; Liang, X; Sali, A; Stecula, A; Yee, SW | 1 |
1 review(s) available for erlotinib and alfuzosin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for erlotinib and alfuzosin
| Article | Year |
|---|---|
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
Topics: Drug Discovery; HEK293 Cells; Humans; Ligands; Molecular Docking Simulation; Organic Cation Transporter 1; Small Molecule Libraries | 2017 |